Press release content from Business Wire. The AP news staff was not involved in its creation.
New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology’s PBI-06150 Against SARS-CoV-2
March 17, 2021 GMT
An article published last week in the
Journal of Biomedicine & Pharmacotherapy ( www.elsevier.com/locate/biopha; Vol 138 (2021) 111457) presents
in vitro evidence for significant inhibition of SARS-CoV-2 by oleandrin and a defined extract of
N. oleander (developed by Phoenix Biotechnology, Inc. and designated as PBI-06150), as well as
in vivo evidence of the safety and efficacy of PBI-06150.
ADVERTISEMENT
The
Journal of Biomedicine & Pharmacotherapy is an open access, peer-reviewed medical journal covering medical applications of pharmacology. It was established in 1956 and is published 10 times a year.
People with high BMI may now receive their COVID-19 vaccine in California
As vaccine efforts commence in many countries, prioritizing who receives the vaccine first is in place. Health workers and front-liners will receive the first doses, followed by those at the most significant risk of dying from the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Now, California state allows individuals with one of ten comorbidities to get their COVID-19 jabs. This comes after obesity being tagged as COVID-19 vaccine eligibility.
Image Credit: Arda Savasciogullari / Shutterstock
Body mass index and obesity
The U.S. Centers for Disease Control and Prevention (CDC) notes that obesity is an underlying health condition defined as a body mass index (BMI) of 30 or higher but less than 40.
Salivary IgG to SARS-CoV-2 after mild COVID-19
A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.
Concerns of COVID reinfection
Symptoms of SARS-CoV-2, the underlying agent for coronavirus disease 2019 (COVID-19), vary massively amongst populations of different age groups and health conditions. Most notably, people over the age of 60, and those with underlying health conditions – predominantly lung and autoimmune – tend to suffer worse than younger individuals. Older age groups especially suffer more fatalities and more serious afflictions.
Researchers explore difference in reactions to SARS-CoV-2 infection between children and adults
The coronavirus disease 2019 (COVID-19) pandemic has claimed over 2.67 million lives in less than a year and a half. However, it is uncommon in children, with less than 2% of the cases being in individuals below the age of 19. Most of these are of mild severity, with the clinical features of severe COVID-19 being rare in this age group.
A new and timely study, which was released on the
medRxiv preprint server, explores the differences in the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults vs. children to help understand how the disease develops and progresses.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DeepVerge PLC: Microtox® BT Evaluation of SARS-CoV-2 from breath test with Clinical Samples
Deepverge PLCMarch 17, 2021 GMT
YORK, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces initial data for ongoing Phase III clinical studies on the detection of SARS-CoV-2 on breath samples and identification of confirmed COVID19 positive patients .
Since Q3 2020, DeepVerge scientists have been working under laboratory conditions with the Spike Protein (“S-Protein”) of SARS-CoV-2 on the SARS-CoV-2 virus inside the Containment Level 3 (“CL3″) laboratories at the University of Aberdeen. In these studies, they have detected and identified the virus S-Protein in quantities at 40 femtogram[i] per millilitre (“Fg/mL”) at close to 100% sensitivity and specificity on DeepVerge’s Microtox® BT[ii] nano